Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
PB
Parabilis Medicines Inc PBLS
$31.91
βΌ -2.03%
($-0.66)
Open
$32.84
Prev Close
$32.57
Day Range
$31.20 β $33.74
52W Range
$24.51 β $42.49
Market Cap
$3.94B
Beta
-1.17
EPS (TTM)
$-2.04
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-06-10 |
| Shares Out. | 116,560,000 |
| Website | parabilismed.com β |
| Phone | 16179459510 |
| Revenue | $148,000 |
| Gross Profit | $148,000 |
| Net Income | -$46.9M |
| Total Assets | $1.18B |
| Total Liabilities | $127.5M |
| Equity | $1.05B |
About Parabilis Medicines Inc
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between Ξ²-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/Ξ²-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Parabilis Medicines Inc is a publicly traded company under the ticker symbol PBLS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
11 analysts (2026-09-01)